GGrantIndex
← Search

GENE EXPRESSION CORE

$139,980P30FY2010CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739Paper 39737640Paper 39726772Paper 39711559Paper 39711135Paper 39684443Paper 39677775Paper 39677720Paper 39677022Paper 39671500Paper 39671496Paper 39630148Paper 39609428Paper 39604567Paper 39603869Paper 39574899Paper 39564580Paper 39554114Paper 39436696Paper 39400608Paper 39384405Paper 39342284Paper 39321266Paper 39311710Paper 39282307Paper 39266537Paper 39264810Paper 39215796Paper 39201277Paper 39191549Paper 39147413Paper 39139560Paper 39136655Paper 39120971Paper 39091762Trial NCT05073848Trial NCT05053737Trial NCT05006040Trial NCT04993859Trial NCT04988490Trial NCT04973007Trial NCT04963283Trial NCT04940468Trial NCT04925193Trial NCT04922112Trial NCT04916990Trial NCT04882111Trial NCT04866758Trial NCT04863092Trial NCT04634110Trial NCT04611022Trial NCT04565457Trial NCT04558138Trial NCT04544592Trial NCT04541407Trial NCT04535102Trial NCT04520867Trial NCT04486573Trial NCT04471363Trial NCT04408092Trial NCT04305366Trial NCT04300478Trial NCT04294693Trial NCT04208243Trial NCT04092803Trial NCT04091867Trial NCT04066218Trial NCT04042935Trial NCT04035408Trial NCT04028167Trial NCT04028063Trial NCT04001101Trial NCT03995082Trial NCT03976193Trial NCT03970226Trial NCT03958565Trial NCT03900793Trial NCT03891654Trial NCT03881098Trial NCT03781154Trial NCT03734653Trial NCT03617679Trial NCT03325634Trial NCT01886859Trial NCT01426334Trial NCT01232829Trial NCT00778167Patent 9434994Patent 8734778Patent 8715649Patent 8343502Patent 8337830Patent 8221763Patent 8153136Patent 8067559Patent 7910315Patent 7595060Patent 7563447Patent 7465454Patent 7083787

Abstract

The Gene Expression Core is dedicated to making molecular gene expression technology available to cancer center members in a user-friendly manner. We utilize oligonucleotide arrays, cDNA arrays and quantitative RNA methodologies to investigate the changes in gene expression. Affymetrix technology is used for the oligonucleotide arrays. The Affymetrix platform has a large number of products, all of which are supported by the Core, including expression arrays and SNP analysis. Custom spotted arrays are constructed from sequenceverified clones, selected oligonucleotide sets, as well as commercially available arrays from Agilent and CodeLink. Quantitation of selected genes is made possible using real time PCR. With these capabilities, the objectives of the Gene Expression Core facility are to: 1) Analyze gene expression using both oligonucleotide and cDNA arrays;2) Facilitate gene discovery;3) Accurately quantitate gene expression using real time PCR; 4) Provide support for data analysis and bioinformatics by our data mining tool and our cluster analysis capabilities. This facility has a commitment to utilizing a variety of approaches for expression analysis. This core was established in response to the technological advances in gene array, as well as the demand for high throughput expression analysis and genomic investigation to investigate pathogenesis, therapeutics, genetic susceptibility and gene discovery in cancer research. The informatics aspect is of paramount importance, and five distinct analysis programs, as well as a network, are used to store, share and analyze the data. The facility has the capability and flexibility to adapt as the field of array technology changes. These changes are translated into upgrading the facility and its services. More complex analysis of gene expression arrays is available to members through the Biostatistics/Bioinformatics Core. To date, the Core is one of the highest volume Affymetrix microarray facilities in academia in the country, having performed over 6366 microarrays including test arrays on 4816 samples over 5 years for nearly 160 investigators. On average, 75% of the user's are Cancer Center members. Data from the Core has been incorporated into over 100 published manuscripts to date. The Core is also partly supported by an NHLBI Microarray Center Consortium award to Dr. Geraci. This support has made it possible for the Core to double its capacity in the past year. Future directions of the Core include upgraded technologies and the use of high-throughput analysis in translational research.

View original record on NIH RePORTER →